Managing Diabetes with Hydrogel Drug Delivery
Managing Diabetes with Hydrogel Drug Delivery
复制标题
DOI：
10.1002/adtp.202300127
复制
发表时间：
2023-06
影响因子：
4.6
通讯作者：
Yuanhui Xiang;Bo Su;Dongping Liu;M. Webber
中科院分区：
文献类型：
--
作者：
Yuanhui Xiang;Bo Su;Dongping Liu;M. Webber
糖尿病是社会面临的最紧迫的医疗保健挑战之一。胰岛素信号功能失调会导致糖尿病，导致血糖不稳定和许多相关并发症。虽然外源性胰岛素的施用对于实现血糖控制至关重要，但给药准确性和时间安排的问题仍然存在。基于水凝胶的药物递送系统已被广泛探索用于控制蛋白质释放，包括在长效和口服胰岛素递送中的应用。最近，人们的努力集中在具有葡萄糖定向控制释放胰岛素和胰高血糖素的可注射水凝胶上，旨在采用更自主和仿生的血糖控制方法。这些材料通常使用基于蛋白质的传感机制或通过合成芳基硼酸盐结合葡萄糖来实现葡萄糖定向释放。尽管这一领域取得了进展，但仍然需要更精确的治疗时机以维持健康的血糖稳态，从而为进一步研究和创新提供机会。这篇综述总结了基于水凝胶的胰岛素和胰高血糖素输送的现状，深入探讨了潜在的好处、未来的方向以及为实现临床影响而必须克服的挑战。
Diabetes is one of the most pressing healthcare challenges facing society. Dysfunctional insulin signaling causes diabetes, leading to blood glucose instability and many associated complications. While the administration of exogenous insulin is then essential for achieving glucose control, issues with dosing accuracy and timing remain. Hydrogel‐based drug delivery systems have been broadly explored for controlled protein release, including for applications in long‐lasting and oral insulin delivery. More recently, efforts have focused on injectable hydrogels with glucose‐directed controlled release of insulin and glucagon, aiming for more autonomous and biomimetic approaches to blood glucose control. These materials typically use protein‐based sensing mechanisms or glucose binding by synthetic aryl boronates for glucose‐directed release. Despite advancements in this area, there remains a need for more precise timing of therapeutic availability to afford healthy blood glucose homeostasis, providing an opportunity for further research and innovation. This review summarizes the current state of hydrogel‐based delivery of insulin and glucagon, with insights into the potential benefits, future directions, and challenges that must be overcome to achieve clinical impact.